Cargando…

Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”

Detalles Bibliográficos
Autores principales: Concordet, Didier, Gandia, Peggy, Montastruc, Jean-Louis, Bousquet-Mélou, Alain, Lees, Peter, Ferran, Aude A., Toutain, Pierre-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007434/
https://www.ncbi.nlm.nih.gov/pubmed/31802402
http://dx.doi.org/10.1007/s40262-019-00852-3
_version_ 1783495317972320256
author Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
author_facet Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
author_sort Concordet, Didier
collection PubMed
description
format Online
Article
Text
id pubmed-7007434
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70074342020-02-24 Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?” Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-12-05 2020 /pmc/articles/PMC7007434/ /pubmed/31802402 http://dx.doi.org/10.1007/s40262-019-00852-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Concordet, Didier
Gandia, Peggy
Montastruc, Jean-Louis
Bousquet-Mélou, Alain
Lees, Peter
Ferran, Aude A.
Toutain, Pierre-Louis
Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_full Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_fullStr Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_full_unstemmed Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_short Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_sort authors’ reply to yu et al.: “levothyrox(®) new and old formulations: are they switchable for millions of patients?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007434/
https://www.ncbi.nlm.nih.gov/pubmed/31802402
http://dx.doi.org/10.1007/s40262-019-00852-3
work_keys_str_mv AT concordetdidier authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT gandiapeggy authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT montastrucjeanlouis authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT bousquetmeloualain authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT leespeter authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT ferranaudea authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT toutainpierrelouis authorsreplytoyuetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients